Researchers describe novel reporter proteins for long term expression of therapeutic genes

July 11, 2017
Credit: Mary Ann Liebert, Inc., publishers

A new study showed that the expression levels of a novel secreted reporter protein delivered to an immunosuppressd large animal model could be detected for several months after infusion into the liver, demonstrating the potential to monitor the effectiveness of delivery and ongoing expression of a therapeutic gene. The genes were packaged and delivered to the liver using the nonviral Sleeping Beauty transposon system, as described in an article published in Human Gene Therapy.

In the article entitled "Transgene Expression in Dogs After Liver-Directed Hydrodynamic Delivery of Sleeping Beauty Transposons Using Balloon Catheters," R. Scott McIvor and coauthors from University of Minnesota, and Discovery Genomics, Minneapolis, MN showed that they were able to infuse DNA solutions into the and measure the levels of a reporter protein in the blood for up to 6 weeks. This method could be used for real-time monitoring of the expression of therapeutic delivered to target tissues such as the liver.

Additional research from R. Scott McIvor's laboratory at the University of Minnesota and Discovery Genomics showed the presence of a reporter protein in the blood of immunosuppressed dogs' blood for up to 5.5 months after infusion, compared to up to 6 weeks in the previous study in dogs not treated with an immunosuppressive agent. In the article "Prolonged Expression of Secreted Enzymes in Dogs after Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene therapy of Systemic Disease," Elena Aronovich et al. concluded that more research is needed to identify alternative methods capable of achieving therapeutic levels of the transgene products.

"The work from the McIvor lab has combined the excellent safety and high capacity of non-viral systems, with the durability created by transposon-mediated integration," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "The new breakthrough here is proving that a hydrodynamic liver-targeted delivery process can be scaled up from mice to large mammals, and potentially humans, thus surmounting the obstacle of delivering the therapeutic transposon payload to the liver efficiently."

Explore further: Gene therapy for liver disease advancing with the help of adeno-associated viral vectors

More information: Kendra A. Hyland et al, Transgene Expression in Dogs After Liver-Directed Hydrodynamic Delivery of Sleeping Beauty Transposons Using Balloon Catheters, Human Gene Therapy (2017). DOI: 10.1089/hum.2017.003

Related Stories

Gene therapy for liver disease advancing with the help of adeno-associated viral vectors

December 30, 2016
Liver-directed gene therapy delivered using adeno-associated viral (AAV) vectors to treat diseases such as hemophilia have advanced into human testing. The potential for continued technological improvements to expand the ...

Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A

March 31, 2017
A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward ...

New system for therapeutic gene delivery increases transgene expression up to 100-fold

January 27, 2017
Advanced engineering of a mini-intronic plasmid (MIP) system designed to carry a therapeutic gene can significantly enhance the expression of the transgene delivered using an adeno-associated viral (AAV) vector. The ability ...

Noninvasive intranasal method shows prevention of neurologic effect from metabolic disease

July 10, 2017
Researchers have successfully used a noninvasive intranasal approach to deliver the gene for the enzyme that is deficient in the inherited lysosomal storage disease mucopolysaccharidosis type 1 (MPS 1) to the brains of an ...

Prednisone may improve effectiveness of AAV-based gene therapy by reducing immune response

June 9, 2017
A new study of gene transfer using adeno-associated virus (AAV)-based gene delivery into skeletal muscle of rhesus macaques showed that oral prednisone reduced immune responses to AAV that can weaken expression of the therapeutic ...

Will AAV vectors have a role in future novel gene therapy approaches?

March 20, 2017
Recombinant adeno-associated virus (rAAV) vectors for delivering therapeutic genes have demonstrated their safety in multiple diseases and clinical settings over the years and are a proven and effective tool that can be used ...

Recommended for you

Forgotten strands of DNA initiate the development of immune cells

September 21, 2017
Intricate human physiological features such as the immune system require exquisite formation and timing to develop properly. Genetic elements must be activated at just the right moment, across vast distances of genomic space.

Study reveals an ancient Achilles heel in the human genome

September 21, 2017
In a major study published today, researchers at deCODE genetics use whole-genome data from 14,000 people from across the population of Iceland, including 1500 sets of parents and children, to provide the most detailed portrait ...

Genome editing reveals role of gene important for human embryo development

September 20, 2017
Researchers have used genome editing technology to reveal the role of a key gene in human embryos in the first few days of development. This is the first time that genome editing has been used to study gene function in human ...

A piece of the puzzle: Eight autism-related mutations in one gene

September 19, 2017
Scientists have identified a hotspot for autism-related mutations in a single gene.

Scientists identify key regulator of male fertility

September 19, 2017
When it comes to male reproductive fertility, timing is everything. Now scientists are finding new details on how disruption of this timing may contribute to male infertility or congenital illness.

New assay leads to step toward gene therapy for deaf patients

September 18, 2017
Scientists at Oregon State University have taken an important step toward gene therapy for deaf patients by developing a way to better study a large protein essential for hearing and finding a truncated version of it.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.